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Cancers are metabolic entities wherein cancer cells adapt their metabolism to their
oncogenic agenda and microenvironmental influences. Metabolically different cancer
cell subpopulations collaborate to optimize nutrient delivery with respect to immediate
bioenergetic and biosynthetic needs. They can also metabolically exploit host cells.
These metabolic networks are directly linked with cancer progression, treatment
resistance and relapse. Conversely, metabolic alterations in cancer are exploited for
anticancer therapy, imaging and personalized medicine. These topics were addressed
at the 3rd annual meeting of the International Society of Cancer Metabolism (ISCaM) in
Brussels, Belgium, on 26–29 October 2016.
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INTRODUCTION
Cancers have a high metabolic plasticity allowing cancer cells to survive and proliferate in extreme
microenvironmental conditions often characterized by hypoxia, declining metabolic resources
and acidosis. Over recent years, experimental and clinical evidence increasingly suggested that
metabolic plasticity contributes to tumor progression. It is central to different networks, not
only those directly pertaining to metabolism (including autophagy, cell cannibalism, cooperativity
and commensalism), but also others referring to broader aspects of cancer cell biology,
including genetics, epigenetics, intra- and inter-cellular signaling and the response of tumors
to different anticancer therapies. Consequently, novel therapeutic targets have been identified
and new treatments are being developed aimed at selectively targeting well-identified metabolic
determinants that control phenotypes associated to tumor progression. These phenotypes notably
include cancer stemness, cancer cell migration and invasion, metastasis, angiogenesis, cancer cell
resistance to anticancer treatments and immunity.
To address these important aspects of tumor biology, the International Society of Cancer
Metabolism (ISCaM1) was founded in 2014 as a logical expansion of the International
1http://www.iscams.org/
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Society for the Study of Proton Dynamics in Cancer (ISPDC)
that operated from 2009 to 2014. ISCaM’s scope is to
improve communication and to foster collaboration between
scientists engaged in acidity, proton dynamics, metabolism and
microenvironment in cancer research. On October 26–29th 2016,
ISCaM hold its 3rd annual meeting in Brussels, Belgium. With a
focus on “Metabolic Networks in Cancer,” this multidisciplinary
symposium allowed to exchange most recent knowledge related
to cancer metabolism between fundamental researchers and
clinicians, scientists of international reputation and young
investigators and ISCaM members and the international scientific
community. It was endorsed by the European Organization for
Research and Treatment of Cancer (EORTC) and by the Belgian
Télévie.
During the opening lecture, Douglas Hanahan reported on
metabolic evasion to anti-angiogenic therapy. When a specific
pro-angiogenic pathway is inhibited, the antitumor response
is typically transitory due to compensation by alternative pro-
angiogenic signals, protection by perivascular macrophages
as well as invasion and metastasis. Together with increased
autophagy, the engagement of cancer cells in a metabolic
symbiosis based on swapping lactate for glucose by glycolytic
cancer cells (Sonveaux et al., 2008) was identified as a fourth
mode of resistance (Allen et al., 2016). Metabolic plasticity was at
the core of ISCaM2016 and was addressed in 11 focused sessions.




Cancers with inactivating mutations of genes encoding metabolic
enzymes accumulate metabolites affecting signaling and
supporting aggressive phenotypes. Christian Frezza discussed
the oncogenic role of fumarate, which accumulates when
fumarate hydratase (FH) is inactivated. He presented results
concerning FH-deficient renal cancer cells, found to undergo
a fumarate-dependent epithelial-mesenchymal transition.
The talk by Rodrigue Rossignol was focused on metabolic
consequences of oncogenic HRAS activation. Multidisciplinary
analyses revealed upregulation/activation of several TCA
cycle enzymes. Metabolomics showed a reversal of the
Warburg effect and increased consumption of glutamate.
Aspartate/glutamate carrier AGC2 was proposed as a target
in cells with HRASG12V mutation. Denis Buurman presented
the Seahorse technology for measuring cellular bioenergetics,
explaining how its embedding in Agilent mass spectrometry
created a synergy useful at cellular/molecular levels. Other
presentations introduced phosphoglycolate phosphatase as
a metabolite repair enzyme required for the coexistence of
glycolysis and the pentose phosphate pathway (PPP; by Guido
T. Bommer), the role of lactate dehydrogenases (LDHs) in
metabolic reprogramming of cancer cells and the necessity to
target both isoforms for tumor growth inhibition (by Maša
Ždralevicˇ), characterization of metabolism in complex cancer
cell populations (by Irena Roci), and metabolic profiling
of complex tissues for metabolic phenotyping (by Shonagh
Russell).
AMINO ACID METABOLISM
EACR-sponsored lecturer, Simone P. Niclou, focused on
isocitrate dehydrogenase 1 (IDH1) mutations present in >80%
of diffuse lower grade gliomas. IDH1 is involved in glutamate
and fatty acid synthesis, and regulates cellular redox balance.
Alterations of unrecognized metabolic pathways conferring
growth advantages were reported. Angela M. Otto then
demonstrated aberrant metabolism regulating the malignant
potential of cancers. Her team observed high glutaminolysis
combined with high glycolytic flux providing more anabolic
metabolites to highly metastatic compared to lowly metastatic
breast cancer cells. Mutation of p53 and/or high constitutive
c-Myc activity explain these differences. Hypoxia is the main
microenvironmental feature exerting metabolic effects in tumors.
Milica Vucetic highlighted that maintenance of cellular redox
equilibrium is essential for cell proliferation under hypoxia.
Genetic disruption of the cystine importer xCT inhibited
cell proliferation to a higher extent under hypoxia than in
normoxia. xCT was marked as a promising target. Citrin, a
malate-aspartate mitochondrial shuttle, and argininosuccinate
synthase 1 (ASS1) are other possible targets since they
interfere with the NAD+/NADH ratio. Shiran Rabinovich
showed that ASS1 deficiency in patients with citrin upregulation
increases cytosolic aspartate availability, while sustaining DNA
synthesis/proliferation. These studies exemplified strategies for
designing anticancer therapies based on metabolic aberrations in
cancer cells.
LIPID METABOLISM
Almut Schulze introduced the concept that cancer cell survival
in hostile conditions with limited nutrients relies on enhanced
macromolecule biosynthesis from lipids, which is regulated by
oncogenic signaling. Major discoveries in this field support
the identification of novel potential therapeutic approaches.
She showed that sterol regulatory element binding proteins
(SREBPs) are controlled by the Akt/mTORC1 signaling axis.
The interlacement of metabolism and signaling regulation was
also discussed in endothelium and ovarian cancer. Francisco
Morales-Rodriguez indeed showed that multifunctional enzyme
fatty-acid synthase (FASN) modulates vessel sprouting via
mTOR malonylation. Thomas W. Grunt further reported
that FASN inhibition interferes with receptor-PI3K-mTORC1
signaling, with subsequent lipid redistribution toward storage,
diminution of membrane lipid rafts and signaling lipids,
and impairment of downstream PI3K activity, including
epithelial growth factor (EGF)-receptor/ErbB/HER-function and
expression. Marja Jäättelä underlined how lipid biosynthesis
is needed for lysosomal stability, which is essential for
autophagosome maturation and development of multidrug
resistance in transformed cells. She found that lysosomal heat
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shock protein 70 (Hsp70) enhances the activity of lysosomal acid
sphingomyelinase (ASMase). She is developing/testing ASMase-
inhibiting cationic amphiphilic drugs, including antihistamines,
as novel anticancer therapeutics with promising results, especially
in patients with records of concurrent chemotherapy.
pH DYNAMICS IN CANCER
Jacques Pouysségur discussed therapeutic possibilities of
a metabolic catastrophe when targeting both glycolytic
and oxidative pathways by, e.g., combining inhibitors of
monocarboxylate transporters (MCTs; preventing lactate eﬄux
and stalling glycolysis) with metformin (targeting oxidative
metabolism). He introduced transporters for essential nutrients
as therapeutic targets, highlighting oncogene-regulated amino
acid transporter SLC7A5. Silvia Pastoreková showed that
carbonic anhydrase (CA)IX regulates metabolic adaptions in the
hypoxic, acidic and nutrient-limited tumor microenvironment.
CAIX engages in a feedback loop with hypoxia-inducible
factor-1 (HIF-1) and regulates multiple metabolic enzymes,
enabling cancer cell metabolic adaptability. Holger M. Becker
demonstrated that lactate transport in cancer cells is decreased
by CAII, CAIX or CAXII knockdown, but not by broad CA
inhibition. CAs could thus act as “proton antennae” for MCTs,
facilitating lactate-H+ transport non-catalytically and promoting
cancer cell survival. Proffered paper/poster presentations offered
novel insights into the frequent silencing of urea cycle enzyme
ASS1 in cancer (Alon Silberman); Na+/H+ exchanger NHE1
in cancer cell motility (Laurent Counillon, Stephan J. Reshkin),
dual regulatory roles of LDHB on prolylhydroxylase-2 and, thus,
HIF-1 (Piotr Ban´ski); metabolic effects of targeting MCT1 in vivo
and in vitro (Valéry L. Payen); and MRI-CEST pH imaging in
efficacy assessment of dichloroacetate treatment (Annasofia
Anemone).
MICROENVIRONMENT AND STROMA
This session was dedicated to the interplay between metabolism
and the tumor microenvironment. Guy Eelen showed that
(lymphatic) endothelial cells (ECs) use fatty acid-derived
carbons for the production of deoxyribonucleotides for DNA
synthesis. Massimiliano Mazzone then demonstrated that
hypoxic tumor-associated macrophages (TAMs) upregulate
REDD1, a negative mTOR regulator, which in turn hinders
glycolysis and supports TAMs in generating abnormal blood
vessels. In these communications, targeting EC and TAM
metabolism was shown to normalize blood vessels and to
reduce metastatic dissemination. Two other communications
were dedicated to tumor acidosis. Cyril Corbet showed how
acidosis induces a fatty acid-dependent metabolic shift in
tumors associated with a global change in mitochondrial protein
acetylation that, e.g., leads to partial electron transport chain
complex I inhibition, thus preventing the production of reactive
oxygen species (ROS). Sofia Avnet showed how acidic pH leads
to the secretion of a cocktail of inflammatory and nociceptive
mediators by mesenchymal cells of the bone marrow, which
thereby contribute to cancer-associated bone pain. A proffered
paper presentation by Silvia Lemma from the same group
documented that lactate generated by cancer cells directly fuels
the mitochondrial metabolism of osteoclasts and participates to
bone resorption.
AUTOPHAGY
Patrizia Agostinis reviewed recent findings indicating that
increased autophagy negatively affects immunogenic cell
death, that chloroquine reduces tumor hypoxia and improves
chemotherapeutic efficacy through autophagy-independent
vascular normalization, and that increased expression of BNIP3,
a HIF-induced gene promoting autophagy, correlates with poor
prognosis in melanoma. Nathalie M. Mazure then reported
that BNIP3 and truncation of mitochondrial voltage-dependent
anion channel 1 (VDAC1) contribute to apoptosis resistance in
hypoxic cancers, which can be decreased by silencing p53. Carine
Michiels showed that cytoprotective autophagy contributes
to cancer resistance to taxol. Taxol indeed activates activating
transcription factor 4 (ATF4), which is involved in taxol-induced
autophagy and contributes to adaptation and resistance of breast
cancer cells to chemotherapy in hypoxic tumors. Angelo De
Milito showed how tumor acidosis mediates insensitivity of
cancer cells to chloroquine. Salinomycin was identified as a
potent cytotoxic agent preferentially killing cancer cells in acidic
microenvironmental conditions due to increased intracellular
accumulation of this strong autophagy inhibitor. Breast cancer
stem cells (BCSC) are more sensitive to salinomycin than non-
BCSC, and acidic conditions enhance the ability of salinomycin
to inhibit mammosphere formation. Laura Brohée discussed
the pro-tumorigenic roles of lipins and how lipin inhibitor
propranolol increases the sensitivity of prostate cancer cells to
2-deoxyglucose by inhibiting autophagy.
EPIGENETICS AND OTHER ASPECTS OF
TUMOR METABOLISM
In this session, François Fuks summarized the current knowledge
about DNA (hydroxyl)methylation and RNA modifications in
cancer. This lecture was echoed by Manel Esteller who reviewed
the epigenetic machinery (DNA methyltransferases, methyl-
CpG-binding domain proteins, histone deacetylases, histone
methyltransferases, histone demethylases and polycomb
proteins) involved in the control of DNA methylation.
Perturbations of these systems in cancer lead to abnormal
methylation patterns not only in classical tumor suppressor
genes but also in genes related to non-coding RNAs that possess
growth inhibitory functions. Eyal Gottlieb then provided a
causal link between mutations of metabolic enzymes and
altered epigenetics by showing that loss of function mutations
of succinate dehydrogenase (SDH) increase susceptibility to
cancer by inhibiting α-ketoglutarate-dependent histone and
DNA demethylases. Stine F. Pedersen focused on altered miRNA
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expression in breast cancer. She showed that upregulation of
constitutively active HER2 receptor variant p95HER2 triggers
miR-221/222 and miR-503 expression, which in turn inhibit the
activity of MYB transcription factors and increase Na+-HCO3−-
cotransporter mRNA stability. Cristovão M. Sousa concluded
the session with new data indicating that stroma-associated
pancreatic stellate cells fuel pancreatic cancer cells with alanine,
thus revealing alanine as a TCA cycle fuel alternative to glucose
and glutamine.
METABOLIC CONTROL OF STEMNESS
AND METASTASIS
Aspects of the crosstalk between metabolism and cellular
differentiation/metastasis were discussed. Based on previous
work (Wanet et al., 2014), Patricia Renard elegantly showed
the role of mitochondrial metabolism in mediating hepatocyte
differentiation from bone marrow-derived mesenchymal stem
cells. This team identified the interplay between hepatic
differentiation and mitochondrial biogenesis, highlighting the
role of transcription factors peroxisome proliferator-activated
receptor gamma coactivator 1-α (PGC1-α) and HIF-1. Although
these findings involved untransformed cells, their potential was
also clear for cancer cells, with stemness as an important issue.
Paolo E. Porporato then reported that mitochondrial metabolism
controls cancer cell migration, invasiveness and metastasis
through the production of mitochondrial ROS acting as signaling
molecules (Porporato and Sonveaux, 2015). The perspective of
combining specific chemotherapy regimens that induce moderate
levels of mitochondrial ROS with targeted antioxidant therapies
was discussed. Mojca Pavlin provided evidence that extreme
impairment of metabolic fluxes by metformin treatment and
glucose depletion triggers MDA-MB-231 breast cancer cell
migration and increases their resistance to anoikis. Antoinette
van Weverwijk identified by in vivo screening metabolic
enzymes involved in breast cancer invasiveness. Myriam Y. Hsu
showed that lactate transporter MCT1 promotes metastasis by a
mechanism independent of its transporter activity.
THERAPY
Despite high incidence of chemoresistance, cisplatin still
stands as the first-line agent for epithelial malignancies.
Cisplatin cytotoxicity is due to the formation of DNA-adducts,
but other mechanisms are involved, including interaction
with phospholipids, proteins, RNA and mitochondrial DNA
(mtDNA), leading to energetic dysfunctions. Monica Montopoli
confirmed this hypothesis through metabolomic profiling of
cisplatin-resistant cells that showed increased use of glucose
and PPP metabolism. Chemosensitization may be achieved
by limiting the enzymatic activity of glucose-6-phosphate
dehydrogenase and the PPP. Anna Maria Porcelli underlined that
energetic dysfunctions elicited by cisplatin can cause resistance
following polychemotherapy with cisplatin and antimitogenic
drugs like paclitaxel. Platinum adduct-mediated metabolic
alterations indeed drive cells into a low-proliferative state. As for
chemotherapy, cancer metabolism is an important determinant
of cancer radiosensitivity, in that ionizing radiation is cytotoxic
via ROS-dependent DNA damage and that mitochondria play a
central role in cellular responses to redox stress. Debora Grasso
showed that radioresistant head-and-neck carcinoma cells shift
to a more oxidative metabolism compared to sensitive cells. Sven
de Mey further showed that treatment of preclinical models of
colorectal cancer with phenformin significantly radiosensitized
cancer cells under hypoxia, possibly by improving tumor
oxygenation via inhibition of mitochondrial complex I.
IMAGING
Imaging technologies provide a better understanding of the
interplay between tumor behavior and its microenvironment
and are becoming increasingly relevant for clinical settings.
Studying cancer cell dissemination in metastasis using time-
resolved live-cell and intravital microscopy, Peter Friedl showed
that multicellular clusters migrate collectively, which leads
to collective organ colonization. However, in conditions of
severe hypoxia, these clusters dissociate, resulting in single cell
migration. To be able to distinguish between directed and
random cell migration, Tina Freisinger reported on applied
time-lapse microscopy in Ibidi culture chambers in which the
migratory behavior of cancer cells exposed to chemotactic
gradients can be analyzed. Time-lapse microscopy is also the
basis of IncuCyte Zoom, introduced by Toon De Roeve, with
which images of cell cultures are collected in real-time over
prolonged times and continuously evaluated for numerous
cell processes, including proliferation, migration and stem cell
differentiation. The fate of isotope-labeled molecules in tumors
can be followed by positron emission tomography (PET). In a
preclinical report by Vincent F. Van Hée, [18F]-3-fluorolactate
served as a new tracer of lactate uptake by oxidative cancer
cells and for monitoring uptake inhibition by anticancer drugs
targeting the lactate transporter MCT1 in vivo.
BIOMARKERS
Biomarkers, whether genomic, proteomic or imaging, are critical
components for assessing metabolic compartmentation between
cancer cells, stromal cells and crosstalk between cancer and
stroma. Arkaitz Carracedo used cutting edge bioinformatics to
uncover metabolic switches that cooperate with phosphatase
and tensin homolog (PTEN) loss to promote prostate cancer
aggressiveness and metastasis. Aziz Aiderus analyzed gene
expression from a set of 973 ER+ breast cancers. He showed
that increased expression of a fatty acid metabolic signature
(including carnitine palmitoyltransferase CPT1) was associated
with good prognosis, which was validated in an independent
test set as well as in lung and gastric cancers. Mitochondrial
biomarkers were discussed next. Giuseppe Gasparre introduced
several lines of evidence that mtDNA mutations can be
heterogeneous and, in each case, the site and amount of
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mutational burden could be correlated with a metabolic
phenotype, raising the idea that mtDNA can be interrogated as
a biomarker. Gyorgy Szabadkai developed a massively parallel
biclustering analytical approach to investigate ∼1,000 nuclear
encoded mitochondrial gene expression patterns (nMGEP) in
relationship to metabolic phenotypes and found that nMGEPs
were highly predictive of metabolic subtypes in Luminal A and
B breast cancers.
CONCLUSION
Metabolic plasticity is a major determinant of cancer progression
supported by the expression in cancer cells of different
enzyme and transporter isoforms that activate alternative
metabolic pathways under hostile conditions, and by metabolic
relationships established between cancer and stromal cells. One
of the critical contributions of the tumor stroma was illustrated
by Pawel Swietach in the closing lecture of ISCaM2016, which
reported that, when cancer cells suffer for inadequate blood
perfusion, stromal cells can handle metabolic wastes through a
syncytial network of cytoplasms interconnected by gap junctions.
The international Society of Cancer Metabolism aims to
promote interactions between basic and clinical researchers and
between young and senior scientists, which was facilitated by
the relatively small size of the meeting (189 participants) and its
international composition (attendees represented 30 countries).
Social activities were organized. Oral and poster communications
were dispatched to sessions focusing on emerging aspects of
cancer metabolism that were co-chaired by a principal and by a
young investigator. Prizes were awarded to young investigators
who delivered best scientific presentations. Oral presentation
prizes went to Cyril Corbet (1st ISCaM prize), Alon Silberman
(2nd Organizers’ prize) and Debora Grasso (3rd Organizer’s
prize). Their studies are highlighted above. Poster presentations
prizes went to Irena Roci (1st ISCaM prize for a study using
isotope tracing for metabolic characterization of complex cancer
cell populations), Myriam Y. Hsu (2nd EACR prize, study
detailed above) and Maša Ždralevic´ (3rd EACR prize for a
study showing that co-silencing LDHA and LDHB enhances
metformin cytotoxicity). In line with ISCaM’s objective to
improve the outcome of cancer patients through the discovery
and development of new anticancer drugs, several potential
anticancer targets related to tumor metabolism were presented.
Conclusively, ISCaM2016 provided the audience with most
recent discoveries on metabolic networks in cancer. This major
topic of investigation will be discussed and updated at the
ISCaM2017 meeting in Bertinoro, Italy, 19–21 October 20172.
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